New targeted drug KIVU-305 enters first human tests for Hard-to-Treat cancers
Disease control
Not yet recruiting
This early-phase study tests a new drug called KIVU-305 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target and attack cancer cells while sparing healthy ones. The main goal is to find the safest dose and check …
Phase: PHASE1 • Sponsor: Kivu Bioscience Inc. • Aim: Disease control
Last updated Apr 29, 2026 15:05 UTC